title: [Experience about more than 2000 renal transplantations at the university of Brussels].
abstract: Since 1965, more than 2000 renal transplantations (including more than 100 living-donor transplantations) have been performed at the University of Brussels. An end-stage renal disease patient candidate to renal transplantation will be therefore followed from his enrolment on the waiting list to the long-term post-transplant period. Improvement in the outcome of renal transplantation is achieved due to better knowledge in many fields of medicine, such as immunology, infectious disease, metabolic diseases (hyperlipemia, diabetes mellitus), pharmacology, use of immunosuppressive regimen, a more adequate cardiovascular prevention and treatment. If the best results were achieved with kidneys from living donors, the graft survival rate at the University of Brussels was nearly 80% for the last period (2000-2006). Unfortunately, renal transplantation cannot cure certain comorbid conditions and even may promote them: infectious diseases, neoplasia, metabolic disorders (e.a diabetes mellitus, hyperlipemia). Many efforts have to be done to develop less toxic and more immune selective therapeutic strategies. Living donation and extension of the pool of cadaveric donors will reduce the length of time spent on the waiting list and will significantly impact on mortality and morbidity after kidney transplantation.
authors.affiliation: Service de Néphrologie, Dialyse et Transplantation rénale, Hôpital Erasme, U.L.B., Bruxelles. dabram@ulb.ac.be
authors.forename: P
authors.initials: P
authors.lastname: Madhoun
authors.forename: M
authors.initials: M
authors.lastname: Wissing
authors.forename: N
authors.initials: N
authors.lastname: Broeders
authors.forename: L
authors.initials: L
authors.lastname: Ghisdal
authors.forename: A
authors.initials: A
authors.lastname: Hoang
authors.forename: P
authors.initials: P
authors.lastname: Loi
authors.forename: D
authors.initials: D
authors.lastname: Michalsky
authors.forename: R
authors.initials: R
authors.lastname: Bollens
authors.forename: V
authors.initials: V
authors.lastname: Donckier
authors.forename: L
authors.initials: L
authors.lastname: Hooghe
authors.forename: F
authors.initials: F
authors.lastname: Janssen
authors.forename: M
authors.initials: M
authors.lastname: Hall
authors.forename: M
authors.initials: M
authors.lastname: Depierreux
authors.forename: P
authors.initials: P
authors.lastname: Kinnaert
authors.forename: P
authors.initials: P
authors.lastname: Vereerstraeten
authors.forename: D
authors.initials: D
authors.lastname: Abramowicz
mesh_terms: D001530:Belgium / Q000453:epidemiology; D002102:Cadaver; D006085:Graft Survival; D006785:Hospitals, University; D006801:Humans; D016030:Kidney Transplantation / Q000401:mortality / Q000502:physiology / Q000706:statistics & numerical data*; D019520:Living Donors; D012189:Retrospective Studies; D014019:Tissue Donors; D017211:Treatment Failure; D016896:Treatment Outcome